Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients

Journal of Hepatology

Volumn 50, Issue 6, 2009, Pages 1074-1083

  Bottero, Julie ^a   Lacombe, Karine ^a,b,c   Guéchot, Jérôme ^c   Serfaty, Lawrence ^c   Miailhes, Patrick ^d   Bonnard, Philippe ^e   Wendum, Dominique ^c   Molina, Jean Michel ^f   Lascoux Combe, Caroline ^f   Girard, Pierre Marie ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL TENON   (France)

^f SAINT LOUIS HOSPITAL   (France)

Author keywords

Biological markers; Chronic hepatitis B; Diagnostic test; HIV; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; UREA;

ADULT; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; THROMBOCYTE COUNT;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; BIOPSY; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; FEMALE; HEPATITIS B; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 67349085214     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.022     Document Type: Article

References (46)

1. Rosenthal E., Pialoux G., Bernard N., Pradier C., Rey D., Bentata M., et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 14 (2007) 183-188
2. Custer B., Sullivan S.D., Hazlet T.K., Iloeje U., Veenstra D.L., and Kowdley K.V. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 38 10 Suppl 3 (2004) S158-S168
3. Ockenga J., Tillmann H.L., Trautwein C., Stoll M., Manns M.P., and Schmidt R.E. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 27 (1997) 18-24
4. Thio C.L., Seaberg E.C., Skolasky Jr. R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 (2002) 1921-1926
5. Puoti M., Spinetti A., Ghezzi A., Donato F., Zaltron S., Putzolu V., et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24 (2000) 211-217
6. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 (2001) 495-500
7. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614-2618
8. Castera L., Denis J., Babany G., and Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?. J Hepatol 46 (2007) 528-529 author reply 529-530
9. Cales P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005) 1373-1381
10. Nguyen-Khac E., and Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol 18 (2006) 1321-1325
11. Macias J., Giron-Gonzalez J.A., Gonzalez-Serrano M., Merino D., Cano P., Mira J.A., et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55 (2006) 409-414
12. Loko M.A., Castera L., Dabis F., Le Bail B., Winnock M., Coureau G., et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 103 (2008) 1973-1980
13. Soriano V., Barreiro P., and Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 57 (2006) 815-818
14. Barreiro P., Rodriguez-Novoa S., Labarga P., Ruiz A., Jimenez-Nacher I., Martin-Carbonero L., et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 195 (2007) 973-979
15. Lacombe K., Massari V., Girard P.M., Serfaty L., Gozlan J., Pialoux G., et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 20 (2006) 419-427
16. Gandhi R.T. Guideline watch. New guidelines on treating chronic hepatitis B and C in HIV-coinfected patients. AIDS Clin Care 17 (2005) 65
17. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
18. Bani-Sadr F., Carrat F., Bedossa P., Piroth L., Cacoub P., Perronne C., et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 20 (2006) 525-531
19. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
20. Kelleher T.B., Mehta S.H., Bhaskar R., Sulkowski M., Astemborski J., Thomas D.L., et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43 (2005) 78-84
21. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 (2005) 1867-1873
22. Zeng M.D., Lu L.G., Mao Y.M., Qiu D.K., Li J.Q., Wan M.B., et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 42 (2005) 1437-1445
23. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
24. Sterling R.K., Lissen E., Clumeck N., Sola R., Correa M.C., Montaner J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 (2006) 1317-1325
25. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer E., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 (2002) 986-992
26. Giannini E., Risso D., Botta F., Chiarbonello B., Fasoli A., Malfatti F., et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 163 (2003) 218-224
27. Halfon P., Bourliere M., Penaranda G., Deydier R., Renou C., Botta-Fridlund D., et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 4 (2005) 6
28. Hui A.Y., Chan H.L., Wong V.W., Liew C.T., Chim A.M., Chan F.K., et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 100 (2005) 616-623
29. McNeil B.J., and Hanley J.A. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 4 (1984) 137-150
30. Poynard T., Halfon P., Castera L., Munteanu M., Imbert-Bismut F., Ratziu V., et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 53 (2007) 1615-1622
31. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
32. Larsen C., Pialoux G., Salmon D., Antona D., Piroth L., Le Strat Y., et al. Prévalence des hépatites B et C dans la population. VIH+, France, Juin 2004. BEH 23 (2005) 109-112
33. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 7 (2007) 40
34. Leroy V., Hilleret M.N., Sturm N., Trocme C., Renversez J.C., Faure P., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 775-782
35. Cacoub P., Carrat F., Bedossa P., Lambert J., Penaranda G., Perronne C., et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study-ANRS HC02. J Hepatol 48 (2008) 765-773
36. Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 (2003) 222-230
37. Ngo Y., Benhamou Y., Thibault V., Ingiliz P., Munteanu M., Lebray P., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 3 (2008) e2573
38. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
39. Guechot J., Poupon R.E., Giral P., Balkau B., Giboudeau J., and Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 20 (1994) 388-393
40. Sebastiani G., Vario A., Guido M., and Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 13 (2007) 525-531
41. Negredo E., Cruz L., Paredes R., Ruiz L., Fumaz C.R., Bonjoch A., et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 34 (2002) 504-510
42. Fisher S.D., Miller T.L., and Lipshultz S.E. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 185 (2006) 1-11
43. Taillan B., Roul C., Fuzibet J.G., Vinti H., Pesce A., Bayle J., et al. Circulating anticoagulant in patients seropositive for human immunodeficiency virus. Am J Med 87 (1989) 238
44. Ganem D., and Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
45. Halfon P., Bacq Y., De Muret A., Penaranda G., Bourliere M., Ouzan D., et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 395-402
46. Lambert J., Halfon P., Penaranda G., Bedossa P., Cacoub P., and Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 54 (2008) 1372-1378